COMPANY

Astrocyte Pharmaceuticals Inc.

HQ: Groton, CT source · astrocytepharma.com ↗ · New England

Astrocyte Pharmaceuticals is developing neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders. From company website Source · Oct 12, 2026

Location: Groton, CT · source · Oct 28, 2022

Profile checked Oct 10, 2026

$9.5MRaised (2 yrs)6NIH grants

Funding and NIH signals

NIH award NIH awarded $1.5M (SBIR Phase II 5R44NS137896-02, continuation, notice Aug 24, 2026); 2 NIH awards totaling $1.9M in the last 12 months. NIH RePORTER 5R44NS137896-02 (Aug 24, 2026)
Evidence (2 events)
- Aug 24, 2026 · NIH RePORTER 5R44NS137896-02
  Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS137896-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1499802; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI); Organization type: Domestic For-Profits
- Jul 7, 2026 · NIH RePORTER 1R41DA064479-01
  Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 1R41DA064479-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 399680; Administering IC: National Institute on Drug Abuse; Project title: Preclinical efficacy of AST-004 as a treatment for substance use disorder; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series B · $9.5M · announced Sep 30, 2026 Company release ↗
Source quote
- Sep 30, 2026 · Company release ↗
  “– Astrocyte Pharmaceuticals Inc. , a pioneering clinical-stage biotechnology company developing first-in-class cerebroprotective therapies for concussion, traumatic brain injury (TBI) and stroke, today announced the completion of a $9.5 million Series B financing round”

Raises announced in these releases: $9.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 30, 2026 Raise Private equity round — Series B: $9.5M (total, as published), announced Sep 30, 2026. Source: company's own press page. source ↗
Sep 30, 2026 Raise Series B · $9.5M source ↗
Aug 24, 2026 Grant Government grant — SBIR: $1.5M (annual award, as published), announced Aug 24, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 7, 2026 Grant Government grant — STTR: $399,680 (annual award, as published), announced Jul 7, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Jun 17, 2025 Grant Government grant: $3M (total, as published), announced Jun 17, 2025. Source: company's own press page. source ↗
Jun 10, 2025 Grant Government grant — SBIR: $1.5M (annual award, as published), announced Jun 10, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Funding

Raised: $9.5M. Last 2 years.

Sep 30, 2026 Private equity round — Series B: $9.5M (total, as published), announced Sep 30, 2026. Source: company's own press page. source ↗
Aug 24, 2026 Government grant — SBIR: $1.5M (annual award, as published), announced Aug 24, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 7, 2026 Government grant — STTR: $399,680 (annual award, as published), announced Jul 7, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Jun 17, 2025 Government grant: $3M (total, as published), announced Jun 17, 2025. Source: company's own press page. source ↗
Jun 10, 2025 Government grant — SBIR: $1.5M (annual award, as published), announced Jun 10, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

NIH awards 6

Annual award amounts. Total $4.0M.

Aug 7, 2019 NIH award 5R44NS093756-04 FY2019: $1,499,342 awarded for that fiscal year; activity R44 (SBIR); PI LISTON, THEODORE E; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. Preclinical development of source ↗
Apr 26, 2019 NIH award 5R41AG062163-02 FY2019: $98,118 awarded for that fiscal year; activity R41 (STTR); PI LECHLEITER, JAMES D; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. Astrocyte activation by small source ↗
Sep 19, 2018 NIH award 2R44NS093756-03 FY2018: $1,496,476 awarded for that fiscal year; activity R44 (SBIR); PI LISTON, THEODORE E; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. Preclinical development of source ↗
Sep 18, 2018 NIH award 1R41AG062163-01 FY2018: $199,830 awarded for that fiscal year; activity R41 (STTR); PI LECHLEITER, JAMES D; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. Astrocyte activation by smal source ↗
Aug 26, 2016 NIH award 5R41NS093756-02 FY2016: $251,420 awarded for that fiscal year; activity R41 (STTR); PI LECHLEITER, JAMES D; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. ASTROCYTE ACTIVATION BY SMAL source ↗
Sep 18, 2015 NIH award 1R41NS093756-01 FY2015: $420,239 awarded for that fiscal year; activity R41 (STTR); PI LECHLEITER, JAMES D; recipient as written: ASTROCYTE PHARMACEUTICALS, INC., CAMBRIDGE, MA. ASTROCYTE ACTIVATION BY SMAL source ↗